FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative-free ketamine product, which it has previously called KETAFREE1. KETAFREE is a generic product, hence the ANDA pathway, and is thus approved with the same label as Ketalar, the first ketamine product approved by FDA…

Source